ES2318575T3 - Interferon beta desamidado. - Google Patents

Interferon beta desamidado. Download PDF

Info

Publication number
ES2318575T3
ES2318575T3 ES05818235T ES05818235T ES2318575T3 ES 2318575 T3 ES2318575 T3 ES 2318575T3 ES 05818235 T ES05818235 T ES 05818235T ES 05818235 T ES05818235 T ES 05818235T ES 2318575 T3 ES2318575 T3 ES 2318575T3
Authority
ES
Spain
Prior art keywords
ifn
protein
composition
deamidated
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05818235T
Other languages
English (en)
Spanish (es)
Inventor
Kenji Furuya
Deborah Johnson-Jackson
Diana Tierra Ruscio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Application granted granted Critical
Publication of ES2318575T3 publication Critical patent/ES2318575T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES05818235T 2004-11-10 2005-11-10 Interferon beta desamidado. Expired - Lifetime ES2318575T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62683704P 2004-11-10 2004-11-10
US626837P 2004-11-10

Publications (1)

Publication Number Publication Date
ES2318575T3 true ES2318575T3 (es) 2009-05-01

Family

ID=36337216

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05818235T Expired - Lifetime ES2318575T3 (es) 2004-11-10 2005-11-10 Interferon beta desamidado.

Country Status (16)

Country Link
US (2) US7595040B2 (enExample)
EP (1) EP1809662B1 (enExample)
JP (1) JP4891250B2 (enExample)
KR (1) KR101330626B1 (enExample)
CN (1) CN101056890B (enExample)
AT (1) ATE415421T1 (enExample)
AU (1) AU2005304486B2 (enExample)
BR (1) BRPI0517697A (enExample)
CA (1) CA2587061C (enExample)
DE (1) DE602005011321D1 (enExample)
ES (1) ES2318575T3 (enExample)
MX (1) MX2007004990A (enExample)
PL (1) PL1809662T3 (enExample)
PT (1) PT1809662E (enExample)
RU (1) RU2404190C2 (enExample)
WO (1) WO2006053134A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
EP2059528A2 (en) * 2006-08-08 2009-05-20 Novartis Ag Recombinant interferon-beta with enhanced biological activity
WO2008137471A2 (en) 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
WO2009045553A1 (en) * 2007-10-05 2009-04-09 Barofold, Inc. High pressure treatment of aggregated interferons
WO2015150468A2 (en) * 2014-04-04 2015-10-08 Ares Trading S.A. Novel ifn beta protein analogs
RU2739261C1 (ru) * 2019-12-31 2020-12-22 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Способ количественного определения антипролиферативной активности интерферона-бета человека

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
TR199901968T2 (xx) 1996-12-24 1999-12-21 Biogen, Inc. Sabit s�v� interferon form�lleri.
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
CA2304808C (en) * 1997-09-23 2011-03-22 Michael Tschope Liquid interferon-.beta. formulations
DE60045247D1 (de) 1999-07-28 2010-12-30 Genentech Inc Zusammensetzungen und verfahren zur behandlung von tumoren
ES2180416B1 (es) 2001-03-12 2004-06-01 BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES, S.A. Procedimiento para la preparacion de mezclas de reaccion estabilizadas, total o parcialmente desecadas, que comprenden, al menos, una enzima, mezclas de reaccion y kits que las contienen.
AR034749A1 (es) * 2001-07-09 2004-03-17 Schering Ag Formulaciones de interferon beta humano
RU2216345C1 (ru) * 2002-03-21 2003-11-20 Закрытое Акционерное Общество "Биокад" Средство, обладающее иммуномодулирующим, противовирусным, противобактериальным, регенерирующим, репаративным, мембрано- и гепатопротекторным действием
KR100541850B1 (ko) * 2003-03-31 2006-01-11 삼성정밀화학 주식회사 인간 인터페론-베타 변이체 및 그의 제조방법

Also Published As

Publication number Publication date
BRPI0517697A (pt) 2008-10-14
CN101056890B (zh) 2012-05-09
PT1809662E (pt) 2009-02-26
WO2006053134A3 (en) 2006-08-31
CA2587061C (en) 2011-08-16
US7595040B2 (en) 2009-09-29
PL1809662T3 (pl) 2009-07-31
KR101330626B1 (ko) 2013-11-18
JP4891250B2 (ja) 2012-03-07
US20090263355A1 (en) 2009-10-22
AU2005304486B2 (en) 2011-08-11
DE602005011321D1 (de) 2009-01-08
CA2587061A1 (en) 2006-05-18
US20060120998A1 (en) 2006-06-08
JP2008519769A (ja) 2008-06-12
ATE415421T1 (de) 2008-12-15
RU2007121515A (ru) 2008-12-20
AU2005304486A1 (en) 2006-05-18
MX2007004990A (es) 2007-06-14
EP1809662A2 (en) 2007-07-25
WO2006053134A2 (en) 2006-05-18
RU2404190C2 (ru) 2010-11-20
CN101056890A (zh) 2007-10-17
KR20070084559A (ko) 2007-08-24
EP1809662B1 (en) 2008-11-26

Similar Documents

Publication Publication Date Title
ES2381674T3 (es) Método de estabilizar proteínas
ES2343518T3 (es) Polipeptidos interferon alfa modificados resistentes a proteasas.
ES2225874T3 (es) Activacion de receptor mediante gas.
Gonzalez et al. Complete cDNA and protein sequence of a pregnenolone 16 alpha-carbonitrile-induced cytochrome P-450. A representative of a new gene family.
ES2279575T3 (es) Analogos de peptidos derivados de receptores del factor de necrosis tumoral.
ES2281175T3 (es) Agonistas y antagonistas selectivos de il-2.
ES2326498T3 (es) Formulacion liquida de g-csf.
JP2021185191A (ja) 炎症性疾患および自己免疫疾患の処置の組成物および方法
BR112020009920A2 (pt) Agonistas parciais de interleucina-2
AU5164590A (en) Use of il-7 in providing medications for stimulation of platelet production
US20090263355A1 (en) Deamidated interferon-beta
ES2310413T3 (es) Factores asociados con el factor de necrosis del tumor receptor de tipo 2 (tnf-r2).
US20090311216A1 (en) Recombinant interferon-beta with enhanced biological activity
US7749735B2 (en) IFNAR2 mutants, their production and use
ES2301167T3 (es) Genes que codifican polipeptidos de la clase de los factores de reguladores de interferones especificos de linfocitos (lsirf).
AU734887B2 (en) Therapeutic agent and treatment for canine intractable dermatitis
ES2206440T3 (es) Una nueva citoquina.
US20030109439A1 (en) KGF polypeptide compositions
RU2607527C2 (ru) Ковалентный моноконъюгат полиэтиленгликоля с тимозином бета 4, устойчивый к деградации в токе крови, и способ его получения
ES2371335T3 (es) Identificación y modificación de epítopos inmunodominantes en polipéptidos.
Goolcharran Deamidation and diketopiperazine formation in model peptides and recombinant human vascular endothelial growth factor